Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival.

@article{Bartel2008BothGL,
  title={Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival.},
  author={Frank Bartel and Juliane Jung and Anja B{\"o}hnke and Elise Gradhand and Katharina Zeng and Christoph Thomssen and Steffen Hauptmann},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2008},
  volume={14 1},
  pages={89-96}
}
PURPOSE Although p53 is one of the most studied genes/proteins in ovarian carcinomas, the predictive value of p53 alterations is still ambiguous. EXPERIMENTAL DESIGN We performed analyses of the TP53 mutational status and its protein expression using immunohistochemistry. Moreover, the single nucleotide polymorphism SNP309 in the P2 promoter of the MDM2 gene was investigated. We correlated the results with age of onset and outcome from 107 patients with ovarian carcinoma. RESULTS In our… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Epithelial ovarian carcinoma.

View 9 Excerpts
Highly Influenced

Commonpolymor - phisms in TP 53 and MDM 2 and the relationship to TP 53 mutations and clinical outcomes in womenwith ovarian and peritoneal carcinomas

WillnerJ GalicV, WollanM
Genes Chromosomes Cancer • 2007

Association between MDM 2309 and age at colorectal cancer diagnosis according to p 53 mutation status

ScainiMC Menin C, De SalvoGL
J Natl Cancer Inst • 2006

Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists • 2006

Evalua - tionof the combined effect of p 53 codon 72 polymor - phismandhotspotmutations in response to anticancer drugs

F Vikhanskaya, MM Siddique, LM Kei
Clin Cancer Res • 2005

MDM 2 is a central node in the p 53 pathway : 12 years and counting

GL Bond, LevineAJ HuW
Curr Cancer DrugTargets • 2005

Similar Papers

Loading similar papers…